SCHEDULE: Richard Jacinto II Boosts DiaMedica Stake to 9.6%
Beneficial Ownership Report
Richard Jacinto II has increased his beneficial ownership in DiaMedica Therapeutics Inc. to 9.6% of outstanding Voting Common Shares.
Summary
- Richard Jacinto II beneficially owns 4,958,823 Voting Common Shares of DiaMedica Therapeutics Inc.
- This ownership represents 9.6% of the total outstanding Voting Common Shares.
- The percentage is calculated based on 51,688,913 Voting Common Shares outstanding as of August 8, 2025, as disclosed in DiaMedica's Form 10-Q filed on August 12, 2025.
- The shares are held by NFS/FMTC Roth IRA FBO Richard Jacinto II, with Richard Jacinto II as the beneficiary.
- Richard Jacinto II holds sole voting and sole dispositive power over all 4,958,823 shares.
- The securities were not acquired and are not held for the purpose of changing or influencing the control of the issuer.
Sentiment
Score: 7
Explanation: The increase in beneficial ownership by a significant individual investor to a 9.6% stake is generally viewed as a positive signal of confidence in the company's prospects, although the filing itself is purely informational regarding ownership.
Positives
- A significant individual investor, Richard Jacinto II, has increased his beneficial ownership to 9.6%, which can be interpreted as a signal of confidence in DiaMedica Therapeutics Inc.
Future Outlook
This filing does not contain any forward-looking statements or guidance from the company or the reporting person regarding future operations or financial performance.
Industry Context
An increase in a significant individual investor's stake, as reported in a Schedule 13G, can sometimes signal a positive outlook for the company within its industry, suggesting that a knowledgeable investor sees value or potential for growth. However, this filing does not provide specific industry-related analysis.
Stakeholder Impact
- Shareholders may view the increased stake by Richard Jacinto II as a positive indicator of investor confidence in DiaMedica Therapeutics Inc., potentially influencing market sentiment.
Key Dates
| Date | Description |
|---|---|
| 08/08/2025 | Date as of which 51,688,913 Voting Common Shares of the Issuer were outstanding, used for percentage calculation. |
| 08/12/2025 | Date the Issuer's Form 10-Q was filed with the SEC, disclosing the outstanding share count. |
| 09/30/2025 | Date of the event which required the filing of this statement. |
| 11/07/2025 | Date the Schedule 13G Amendment No. 3 was signed and filed. |
Recommendation
holdRichard Jacinto II has increased his beneficial ownership in DiaMedica Therapeutics Inc. to 9.6%, indicating a significant individual investor's confidence. While this is a positive signal, a Schedule 13G filing primarily reports ownership and does not provide comprehensive financial or operational details to warrant a stronger recommendation without further analysis. A 'hold' recommendation is appropriate as this news suggests stability or potential upside, but lacks the depth for a 'buy' or 'sell' decision based solely on this filing.
Keywords
DiaMedica Therapeutics, Richard Jacinto II, Beneficial Ownership, Schedule 13G, Voting Common Shares, Stake Increase, Investor Confidence
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.